Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2022-11-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团关于收到政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding government subsidies received during a specific period in 2022. It details the amounts, sources, and accounting treatment of these subsidies. The document is relatively short (2135 characters) and focuses on disclosing financial impacts of government grants rather than presenting a full financial report or audit. It does not contain comprehensive financial statements or detailed management analysis. It is an announcement of a specific financial event (government subsidies) rather than a full report like an Annual Report or Interim Report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-29 Chinese
健民集团关于获得《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving an official approval notice for clinical drug trials from the national drug regulatory authority. It details the drug name, clinical trial approval, drug development status, market context, and regulatory procedures ahead. The document is an announcement of a regulatory event related to drug development and clinical trial approval, not a financial report, earnings release, or management discussion. It is a regulatory announcement informing investors about a material event affecting the company. The document length is short (1731 characters) and it does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-31 Chinese
健民集团关于投资者交流会的公告
Call Transcript Classification · 95% confidence The document is a detailed announcement about a company's investor communication event held via a conference call discussing the company's third quarter 2022 performance and strategic outlook. It includes specifics about the call date, participants, questions asked, and answers given, focusing on financial results and business strategy. The text is not a brief announcement of a report publication, nor is it a formal earnings release with only key highlights. Instead, it is a transcript-like summary of an investor call. Therefore, the document fits best as a Call Transcript (CT). The document length is 2696 characters, which is consistent with a detailed call summary rather than a full annual or quarterly report.
2022-10-26 Chinese
健民集团2022年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2022 Third Quarter Report" of 健民药业集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter of 2022. The report is unaudited as stated. The length is over 12,000 characters, and it includes substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-21 Chinese
健民集团2022年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2022, providing estimated net profit figures and comparisons to the previous year. It explicitly states that the forecast is preliminary and unaudited, and that the final accurate financial data will be disclosed in the official third quarter report. The document is short (854 characters) and serves as an announcement of expected financial results rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. 9M 2022
2022-10-16 Chinese
健民集团2022年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2022 third extraordinary general meeting of shareholders of the company. It includes details about the meeting date, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, but rather the official voting results and meeting details. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2022-10-13 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.